Hi @dachopper,
re your comment " Because... Adult Gvhd is 5 times the number of patients than pediatric", I think you'll find it's even better than that.
The exact quote from CEO Itescu (Feb 28, 2024 Earnings Call) was:
" For adult steroid-refractory acute GVHD, we are collaborating ... to conduct a pivotal trial in adults with this condition in patients who have failed second-line therapies and have no approved therapeutics. This potential market is 5x larger than for pediatric. " (underlining added for emphasis)
and again:
" For adults, adolescents and adults over the age of 12, ruxolitinib is the only approved therapy. And 45% of those who receive ruxolitinib are nonresponders. For the nonresponders, there are no approved therapies."
In other words, it is the adult Ruxolitinib 'non-responder' market ALONE which is 5 x larger than the market for the paediatric indication i.e. those sometimes characterised as RR-aGVHD.
A significant & yet unestimated part of the adult market for SR - aGVHD treatments may 'respond' to Ruxolitinib, and yet attending physicicans may have reservations or outright concerns/ fears about prescribing Ruxolitinib as treatment given it's undeniable toxicity, adverse event profile & Novartis/ Incyte's squirrely behaviour when it comes to producing long-term overall survival i.e. mortality/ morbidity data.
I think we'll find the paradigm shift will generate its own momentum & there will be little need to promote RYONCIL for off-label use.
Cheers
GLTA(LT)H
Hi @dachopper, re your comment " Because... Adult Gvhd is 5...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
0.020(1.95%) |
Mkt cap ! $1.193B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.07 | $1.02 | $7.487M | 7.196M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 39700 | $1.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 86509 | 6 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.05 |
Change
0.020 ( 1.89 %) |
||||
| Open | High | Low | Volume | ||
| $1.02 | $1.07 | $1.02 | 1379563 | ||
| Last updated 15.59pm 07/06/2024 ? | |||||
| MSB (ASX) Chart |